Compare POAI & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POAI | HSCS |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 7.5M |
| IPO Year | N/A | 2022 |
| Metric | POAI | HSCS |
|---|---|---|
| Price | $5.55 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 27.4K | ★ 39.6K |
| Earning Date | 11-14-2025 | 12-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,664,407.00 | $6,250.00 |
| Revenue This Year | $486.27 | N/A |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 320.71 | N/A |
| 52 Week Low | $4.76 | $2.01 |
| 52 Week High | $45.90 | $6.47 |
| Indicator | POAI | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 41.04 |
| Support Level | $5.31 | $2.36 |
| Resistance Level | $6.00 | $2.81 |
| Average True Range (ATR) | 0.55 | 0.26 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 7.16 | 49.12 |
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.